Faes Farma SA (FAE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10010
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Faes Farma SA (Faes Farma) develops, manufactures and commercializes pharmaceutical products and raw materials. The company offers prescription drugs, generic drugs, food supplements, over-the-counter (OTC) medications, baby foods, skin-care treatment products. It exports raw-materials and finished pharmaceutical products to pharmaceutical companies worldwide. Faes Farma also owns Ingaso farm, the animal nutrition and healthcare company. The company operates R&D center in Bilbao, Spain; a laboratory in Lisbon and production plants, subsidiaries and commercial offices in international markets. The company markets its products in Latin America, Asia, Europe, Africa and the Middle East. Faes Farma is headquartered in Madrid, Spain.

Faes Farma SA (FAE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faes Farma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Faes Farma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Faes Farma SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 10
Faes Farma to Form Joint Venture with Eddingpharm 11
Faes Farma Enters into Co- Marketing Agreement with Laboratorios Ordesa 12
Faes Farma Forms Joint Venture With Mexico’s Lab 13
Licensing Agreements 14
Tribute Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 14
Faes Farma Enters into Licensing Agreement with Marathon Pharma 15
FAES Farma Enters into License Agreement with Menarini For Bilastina 16
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 17
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 19
FAES Farma And Pfizer Expand Bilastine License Agreement To 21 New Markets In Latin America 20
Laboratorios SALVAT Enters Into Licensing Agreement With FAES Farma 21
Equity Offering 22
Faes Farma to Raise USD0.53 Million in Offering of Shares 22
Acquisition 23
Faes Farma Acquires Laboratorios Diafarm for USD78.7 Million 23
Faes Farma SA – Key Competitors 24
Faes Farma SA – Key Employees 25
Faes Farma SA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Affiliate 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Faes Farma SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faes Farma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faes Farma SA, Deals By Therapy Area, 2012 to YTD 2018 8
Faes Farma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 10
Faes Farma to Form Joint Venture with Eddingpharm 11
Faes Farma Enters into Co- Marketing Agreement with Laboratorios Ordesa 12
Faes Farma Forms Joint Venture With Mexico's Lab 13
Tribute Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 14
Faes Farma Enters into Licensing Agreement with Marathon Pharma 15
FAES Farma Enters into License Agreement with Menarini For Bilastina 16
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 17
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 19
FAES Farma And Pfizer Expand Bilastine License Agreement To 21 New Markets In Latin America 20
Laboratorios SALVAT Enters Into Licensing Agreement With FAES Farma 21
Faes Farma to Raise USD0.53 Million in Offering of Shares 22
Faes Farma Acquires Laboratorios Diafarm for USD78.7 Million 23
Faes Farma SA, Key Competitors 24
Faes Farma SA, Key Employees 25
Faes Farma SA, Subsidiaries 26
Faes Farma SA, Affiliate 26

List of Figures
Faes Farma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faes Farma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Faes Farma SA (FAE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Energy World Corp Ltd (EWC):電力:M&Aディール及び事業提携情報
    Summary Energy World Corp Ltd (Energy World) is an energy company that produces and sells power and develops liquiefied natural gas projects. The company's activities include design, construction, operation, and maintenance of independent power projects, liquefied natural gas plants, and gas process …
  • Superior Energy Services Inc (SPN):企業の財務・戦略的SWOT分析
    Superior Energy Services Inc (SPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Alkaloid AD Skopje (ALK):企業の財務・戦略的SWOT分析
    Summary Alkaloid AD Skopje (Alkaloid Skopje) is a pharmaceutical company that manufactures cosmetic, pharmaceuticals, botanicals and chemical products. The company’s cosmetic products include skin care products, soaps, hair care products, perfumes and household cleaners. It offers chemical products, …
  • Concurrent Technologies Corporation:企業の戦略・SWOT・財務情報
    Concurrent Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary Concurrent Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Uptake Medical Corp-製薬・医療分野:企業M&A・提携分析
    Summary Uptake Medical Corp (Uptake Med) is a healthcare technology company that develops medical technologies for the treatment of emphysema and lung cancer. The company develops intervapor therapy system, a bronchoscopic procedure in which heated water vapor is delivered to emphysematous lung tiss …
  • Cryosite Ltd (CTE):企業の財務・戦略的SWOT分析
    Summary Cryosite Ltd (Cryosite) is a healthcare solution provider that offers clinical trials outsourced logistics services to research, medical, pharmaceutical, veterinary and biotechnology industries. The company manufactures stem cell products for both therapeutic use and clinical trials. It prov …
  • ING-DiBa AG:企業の戦略的SWOT分析
    ING-DiBa AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • European Institute of Oncology-製薬・医療分野:企業M&A・提携分析
    Summary European Institute of Oncology (IEO) is a research institute that conducts clinical and scientific research on cancer prevention, early diagnosis and treatment of cancer. The institute offers medical care services for breast tumors, lung tumors, cervical tumors, endometrial tumors, thoracic …
  • EpiVax Inc:企業の戦略的SWOT分析
    EpiVax Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Baylor Scott & White Health-製薬・医療分野:企業M&A・提携分析
    Summary Baylor Scott & White Health (Baylor Scott & White) is a non-profit organization that provides medical care services. The organization provides medical education, medical services and conducts medical research. It offers medical services in the area of emergency care, cancer care, behavioral …
  • Under Armour Inc (UAA):企業の財務・戦略的SWOT分析
    Under Armour Inc (UAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • R. R. Donnelley & Sons Company:企業の戦略・SWOT・財務情報
    R. R. Donnelley & Sons Company - Strategy, SWOT and Corporate Finance Report Summary R. R. Donnelley & Sons Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar …
  • Emzor Pharmaceutical Industries Ltd:企業の戦略的SWOT分析
    Emzor Pharmaceutical Industries Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • PKO Bank Polski SA:企業の戦略・SWOT・財務情報
    PKO Bank Polski SA - Strategy, SWOT and Corporate Finance Report Summary PKO Bank Polski SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Wingstop Inc.:企業の戦略・SWOT・財務情報
    Wingstop Inc. - Strategy, SWOT and Corporate Finance Report Summary Wingstop Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Naturgy Energy Group SA:企業の戦略・SWOT・財務分析
    Naturgy Energy Group SA - Strategy, SWOT and Corporate Finance Report Summary Naturgy Energy Group SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Novacyt SA (ALNOV):医療機器:M&Aディール及び事業提携情報
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …
  • Kubota Corporation (6326):企業の財務・戦略的SWOT分析
    Kubota Corporation (6326) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆